Bruton tyrosine kinase inhibitors for multiple sclerosis
2023年4月13日 · Preclinical studies show that BTK inhibition can suppress key pathological features of MS, including B cell activation, CNS lymphocyte infiltration, leptomeningeal inflammation,...
A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis ...
2024年4月17日 · Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic...
Updates in Bruton Tyrosine Kinase Inhibition for Multiple Sclerosis
2022年8月8日 · Bruton tyrosine kinase inhibitors (BTKIs) offer a novel mechanism of action to target the inflammatory and degenerative processes of MS. 1 Several BTKIs are being studied in late-phase clinical trials in people with MS, with the potential to become the next wave within the DMT marketplace.
It's Been a Bumpy Ride for the BTK Inhibitors for MS
2024年10月14日 · The race is on as several drugmakers get closer to the finish line in developing the first Bruton tyrosine kinase (BTK) inhibitor to treat multiple sclerosis (MS). BTK is a nonreceptor enzyme expressed in B cells and myeloid cells, both of which play a significant role in MS pathology. B cells in particular are found in demyelinated areas ...
Bruton tyrosine kinase inhibitors for multiple sclerosis
2023年4月13日 · BTK inhibitors might concurrently target adaptive and innate immune mechanisms in the periphery and central nervous system (CNS). This ability makes BTK inhibitors a promising therapeutic approach for relapsing and progressive forms of multiple sclerosis (MS).
Current Perspectives: Evidence to Date on BTK Inhibitors in the ...
2022年10月6日 · In this article, we review the main effects of BTK inhibitors on different cell types involved in the pathogenesis of MS and summarise recent advances in the development of BTK inhibitors as novel therapeutic approaches in different MS clinical trials. Available data regarding the efficacy and safety of these drugs are described.
Bruton Tyrosine Kinase Inhibition in Multiple Sclerosis
We explore here a novel class of disease-modifying therapies (DMTs): the Bruton tyrosine kinase inhibitors (BTKIs), which might be the missing link in the management of MS, targeting both innate and adaptive arms of the immune system. Decades of neuroimmunologic research substantiate the role of innate and adaptive immunity in the ...
Evobrutinib in multiple sclerosis: challenges and unmet goals
2024年9月19日 · In this issue of The Lancet Neurology, Xavier Montalban and colleagues 6 report the results of two randomised, active-controlled, phase 3 trials (evolutionRMS1 and evolutionRMS2) that evaluate evobrutinib, the first BTK inhibitor developed as a potential therapy for people with multiple sclerosis. The authors found no evidence that evobrutinib ...
BTK inhibitor falters in multiple sclerosis trials - Nature
2024年4月10日 · Bruton’s tyrosine kinase (BTK) inhibitors have shown therapeutic potential in preclinical models of multiple sclerosis (MS), but trial results recently reported at the ACTRIMS Forum (West...
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis ...
2019年5月10日 · Bruton’s tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective oral BTK inhibitor ...